PSMA is a type II transmembrane glycoprotein markedly overexpressed in prostate adenocarcinoma relative to benign tissue, with expression levels increasing in higher-grade, castration-resistant, and metastatic disease. This evidence concerns the gene FOLH1 and metastatic neoplasm.